We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock
YARW

45 hedge funds and large institutions have $68.4M invested in Yarrow Bioscience, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

7% more funds holding

Funds holding: 42 → 45 (+3)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less capital invested

Capital invested by funds: $161M → $68.4M (-$92.3M)

Holders
45
Holders Change
+3
Holders Change %
+7.14%
% of All Funds
1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
12
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$5.6M
2
First Manhattan
First Manhattan
New York
+$2.35M
3
DCM
DAFNA Capital Management
California
+$1.41M
4
AIM
Alambic Investment Management
California
+$1.07M
5
JP Morgan Chase
JP Morgan Chase
New York
+$739K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$4.66M
2
RSCM
Rock Springs Capital Management
Maryland
-$3.25M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$2.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.86M
5
NHAS
Novo Holdings A/S
Denmark
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$148K +$44.8K +2 +25%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$147K +$224K +10 New
Deutsche Bank
28
Deutsche Bank
Germany
$121K -$67.2K -3 -27%
TD Asset Management
29
TD Asset Management
Ontario, Canada
$116K – – –
Renaissance Technologies
30
Renaissance Technologies
New York
$81K -$89.5K -4 -44%
MWNA
31
Marshall Wace North America
New York
$80K +$112K +5 New
Ameriprise
32
Ameriprise
Minnesota
$74K +$112K +5 New
Two Sigma Advisers
33
Two Sigma Advisers
New York
$72K +$22.4K +1 +25%
PPA
34
Parametric Portfolio Associates
Washington
$67K +$112K +5 New
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$66K – – –
Wells Fargo
36
Wells Fargo
California
$64K +$89.5K +4 New
Squarepoint
37
Squarepoint
New York
$59K -$89.5K -4 -50%
Citadel Advisors
38
Citadel Advisors
Florida
$57K +$89.5K +4 New
TA
39
Teachers Advisors
New York
$51K – – –
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$48K +$67.2K +3 New
TRCT
41
Tower Research Capital (TRC)
New York
$44K +$67.2K +3 New
UBS Group
42
UBS Group
Switzerland
$36K +$44.8K +2 New
AIG
43
American International Group
New York
$26K – – –
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$14K – – –
Citigroup
45
Citigroup
New York
$10K – – –
Legal & General Group
46
Legal & General Group
United Kingdom
$5K – – –
Macquarie Group
47
Macquarie Group
Australia
$5K – – –
MAM
48
Meeder Asset Management
Ohio
$5K – – –
Federated Hermes
49
Federated Hermes
Pennsylvania
$3K – – –
AIP
50
Ameritas Investment Partners
Nebraska
$2K – – –
1
2
3

YARW Hedge Fund Activity: Q4 2018 in Review

45 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2018, worth a combined $68.4M — down 57% from $161M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new YARW positions and 10 closed out — a net gain of 3 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was Great Point Partners, adding an estimated $5.6M. The largest seller was OrbiMed, exiting entirely with an estimated $4.66M sold.

  • 45 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2018, up from 42 in Q3 2018.
  • Funds reported $68.4M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2018, down 57% quarter-over-quarter.
  • 13 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2018 and 10 closed out, a net change of +3 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2018 was Great Point Partners, an estimated $5.6M added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2018 was OrbiMed, an estimated $4.66M sold.

Based on aggregated 13F filings for Q4 2018.